Therapeutic applications of gut microbes in cardiometabolic diseases: current state and perspectives

Yuan, Lin,Li, Ying,Chen, Moutong,Xue, Liang,Gu, Qihui,Zhang, Jumei,Zhao, Hui,Xie, Xinqiang,Wu, Qingping
DOI: https://doi.org/10.1007/s00253-024-13007-7
IF: 5
2024-01-21
Applied Microbiology and Biotechnology
Abstract:Cardiometabolic disease (CMD) encompasses a range of diseases such as hypertension, atherosclerosis, heart failure, obesity, and type 2 diabetes. Recent findings about CMD's interaction with gut microbiota have broadened our understanding of how diet and nutrition drive microbes to influence CMD. However, the translation of basic research into the clinic has not been smooth, and dietary nutrition and probiotic supplementation have yet to show significant evidence of the therapeutic benefits of CMD. In addition, the published reviews do not suggest the core microbiota or metabolite classes that influence CMD, and systematically elucidate the causal relationship between host disease phenotypes-microbiome. The aim of this review is to highlight the complex interaction of the gut microbiota and their metabolites with CMD progression and to further centralize and conceptualize the mechanisms of action between microbial and host disease phenotypes. We also discuss the potential of targeting modulations of gut microbes and metabolites as new targets for prevention and treatment of CMD, including the use of emerging technologies such as fecal microbiota transplantation and nanomedicine.
biotechnology & applied microbiology
What problem does this paper attempt to address?
The paper aims to explore the complex interactions between the gut microbiota and its metabolites with the progression of cardiometabolic diseases (CMD), and further conceptualize the mechanisms between microbial and host disease phenotypes. Specifically, the paper focuses on the following aspects: 1. **Relationship between Gut Microbiota and CMD**: - The paper emphasizes how the gut microbiota and its metabolites influence the development of CMD through various pathways, particularly through neuroimmune pathways, immune regulation, or endocrine promotion mechanisms. - Changes in the gut microbiota (such as variations in short-chain fatty acids and trimethylamine N-oxide) may affect the occurrence and development of CMD. 2. **Role of Metabolites**: - Role of Short-Chain Fatty Acids (SCFA) in CMD: SCFA can regulate key metabolic processes such as insulin sensitivity, fat storage, and appetite by activating specific receptors. - Role of Trimethylamine N-oxide (TMAO): TMAO is associated with promoting atherosclerosis and increased cardiovascular disease risk. It can also influence CMD by regulating platelet activation, endothelial dysfunction, and thrombosis. 3. **Application of Emerging Technologies**: - The paper discusses the use of emerging technologies such as fecal microbiota transplantation (FMT) and nanomedicine as new methods for the prevention and treatment of CMD. - These technologies can help regulate the gut microbiota, thereby improving the prognosis of CMD patients. 4. **Potential for Personalized Treatment**: - The paper also explores the importance of identifying specific microbiomes and metabolites to better understand microbial-host changes and the development of disease phenotypes, thereby providing a basis for personalized microbiome therapies. In summary, this review paper aims to reveal the complex interactions between the gut microbiota and CMD, and propose new therapeutic targets and strategies, with the goal of opening new avenues for the prevention and treatment of CMD.